Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAL | P20701 | 10/20 | 0.36 |
| ▸ | ITGB2 | P05107 | 9/20 | 0.36 |
| ▸ | ICAM1 | P05362 | 9/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.34 |
| ▸ | FPR2 | P25090 | 2/20 | 0.33 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4843410 | 0.97 | ITGAL (0.35) | ITGALITGB2ICAM1GRM4FPR2 | |
| SCHEMBL14254786 | 0.91 | ITGAL (0.38) | ITGALITGB2ICAM1FPR2PROKR1 | |
| SCHEMBL4841643 | 0.89 | ITGAL (0.37) | ITGALITGB2ICAM1KDM4ELMNA | |
| SCHEMBL14254788 | 0.86 | ITGAL (0.36) | ITGALITGB2ICAM1KDM4ELMNA | |
| SCHEMBL14254783 | 0.83 | ITGAL (0.38) | ITGALITGB2ICAM1SMN1; SMN2 | |
| SCHEMBL4843339 | 0.82 | ITGAL (0.43) | ITGALITGB2ICAM1 | |
| SCHEMBL14264022 | 0.82 | ITGAL (0.43) | ITGALITGB2ICAM1 | |
| SCHEMBL4850520 | 0.80 | ITGAL (0.38) | ITGALITGB2ICAM1GRM4 | |
| SCHEMBL4848511 | 0.79 | ITGAL (0.43) | ITGALITGB2ICAM1 | |
| SCHEMBL4845213 | 0.78 | ITGAL (0.41) | ITGALITGB2ICAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7342012-B2 | Inhibitors of αLβ2 mediated cell adhesion | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-03-11 | — | — | US | disclosed |
| US-20050148602-A1 | Inhibitors of alphaLbeta2 mediated cell adhesion | TANABE SEIYAKU CO., LTD. | 2005-07-07 | — | — | US | disclosed |
| US-6897225-B1 | Inhibitors of αLβ2 mediated cell adhesion | TANABE SEIYAKU CO., LTD. (JP) | 2005-05-24 | — | — | US | disclosed |
| EP-1307455-B1 | INHIBITORS OF ALPHA-L BETA-2 MEDIATED CELL ADHESION | TANABE SEIYAKU CO (JP) | 2005-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148602-A1 | Inhibitors of alphaLbeta2 mediated cell adhesion | ITGB2, ITGA2B, ITGB1 | ITGAL 6/4885ITGB2 1/4885ICAM1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.